Digest Network Come funziona
Network
/
Società
En
Non verificato

Encoded Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

5 comunicati stampa

Guarda tutti i comunicati
13/05/2026
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Encoded Therapeutics Presents New Clinical Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the ASGCT 2026 Presidential Symposium
Fonte
Encoded Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/05/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Encoded Therapeutics Doses First Patient in Pivotal Study of ETX101 for Dravet Syndrome and Reports Broader Portfolio Progress
Fonte
Encoded Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/04/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Encoded Therapeutics to Present ETX101 Data in Dravet Syndrome at the 2026 ASGCT Presidential Symposium
Fonte
Encoded Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/03/2026
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet Syndrome
Fonte
Encoded Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/01/2026
Igiene alimentare
Salute
Biotecnologia
Farmaceutica
Industria
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
Fonte
Encoded Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0